A systems mechanism for KRAS mutant allele–specific responses to targeted therapy

Isoform-specific Ras signaling is growth factor dependent

(2019) Fiona E. Hood et al.   MOLECULAR BIOLOGY OF THE CELL

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

(2016) Masato Nakamura et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring theKRASG13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

(2016) Eva Segelov et al.   JOURNAL OF CLINICAL ONCOLOGY

A Long Noncoding RNA on the Ribosome Is Required for Lifespan Extension

(2015) Paul B. Essers et al.   Cell Reports

Absolute Quantification of Endogenous Ras Isoform Abundance

(2015) Craig J. Mageean et al.   PLoS One

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response

(2014) Elda Grabocka et al.   CANCER CELL

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Hurdles and Complexities of Codon 13 KRAS Mutations

(2012) Maria Pia Morelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

(2012) Sabine Tejpar et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis

(2012) Hao-Hsuan Jeng et al.   Nature Communications

Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling

(2012) Amy Young et al.   Cancer Discovery

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

(2011) Hiromichi Ebi et al.   JOURNAL OF CLINICAL INVESTIGATION

Mechanistic modeling to investigate signaling by oncogenic Ras mutants

(2011) Edward C. Stites et al.   Wiley Interdisciplinary Reviews-Systems Biology and Medicine

Skyline: an open source document editor for creating and analyzing targeted proteomics experiments

(2010) Brendan MacLean et al.   BIOINFORMATICS

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-RasG13D

(2009) Alessandro Palmioli et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction

(2008) Lothar Gremer et al.   BIOLOGICAL CHEMISTRY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour maintenance is mediated by eNOS

(2008) Kian-Huat Lim et al.   NATURE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE